【华东医药:全资子公司获得美国FDA新药临床试验批准通知】华东医药6月30日公告,全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的注射用HDM2012药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验,适应症为晚期实体瘤。

金融界
Jun 30, 2025
华东医药6月30日公告,全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的注射用HDM2012药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验,适应症为晚期实体瘤。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10